Abstract
A ferret model of severe acute respiratory syndrome (SARS)-CoV infection was used to evaluate the efficacy of an adenovirus vaccine. Animals were subjected to heterologous prime-boost using vectors from human serotype 5 and chimpanzee derived adenoviruses (human AdHu5 and chimpanzee AdC7) expressing spike protein followed by intranasal challenge with SARS-CoV. Vaccination led to a substantial reduction in viral load and prevented the severe pneumonia seen in unvaccinated animals. The same prime-boost strategy was effective in rhesus macaques in eliciting SARS-CoV specific immune responses. These data indicate that a heterologous adenovirus-based prime-boost vaccine strategy could safely stimulate strong immunity that may be needed for complete protection against SARS-CoV infection.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenoviridae / immunology*
-
Administration, Intranasal
-
Animals
-
Antigens, Viral / immunology
-
B-Lymphocytes / immunology
-
Disease Models, Animal
-
Ferrets
-
Humans
-
Immunization, Secondary / methods
-
Lung / immunology
-
Lung / pathology
-
Lung / virology
-
Macaca mulatta
-
Pneumonia / immunology*
-
Pneumonia / prevention & control
-
Severe Acute Respiratory Syndrome / immunology*
-
Severe Acute Respiratory Syndrome / prevention & control
-
Severe acute respiratory syndrome-related coronavirus / growth & development
-
Severe acute respiratory syndrome-related coronavirus / immunology*
-
T-Lymphocytes / immunology
-
Vaccination / methods
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / immunology*
Substances
-
Antigens, Viral
-
Viral Vaccines